目的 探討膽寧片聯(lián)合托尼萘酸片治療非酒精性脂肪肝的臨床療效。方法 選取2016年7月—2018年1月新鄉(xiāng)市中心醫(yī)院收治的102例非酒精性脂肪肝患者為研究對象，根據(jù)隨機區(qū)組設計法將患者分為對照組（51例）和治療組（51例）。對照組患者于飯前30 min口服托尼萘酸片，2片/次，3次/d。治療組在對照組治療的基礎上口服膽寧片，5片/次，3次/d。兩組均連續(xù)治療3個月。觀察兩組患者的臨床療效，同時比較兩組治療前后的體質(zhì)量指數(shù)（BMI）、肝功能、血脂、肝臟CT檢查結(jié)果和血清指標。結(jié)果 治療后，治療組患者的總有效率為98.0%，顯著高于對照組的82.4%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組BMI、丙氨酸氨基轉(zhuǎn)移酶（ALT）、天冬氨酸氨基轉(zhuǎn)移酶（AST）、三酰甘油（TG）和總膽固醇（TC）水平均顯著降低，同組治療前后比較差異具有統(tǒng)計學意義（P<0.05）；且治療后治療組BMI、ALT、AST、TG和TC水平均顯著低于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組的脂肪肝輕重程度分布、肝/脾CT值均顯著改善，兩組比較差異具有統(tǒng)計學意義（P<0.05）；治療后，治療組脂肪肝輕重程度分布、肝/脾CT值顯著優(yōu)于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組超氧化物歧化酶（SOD）顯著升高，丙二醛（MDA）、腫瘤壞死因子-α（TNF-α）水平均顯著降低，同組治療前后比較差異具有統(tǒng)計學意義（P<0.05）；治療后，治療組SOD顯著高于對照組，MDA、TNF-α均顯著低于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結(jié)論 膽寧片聯(lián)合托尼萘酸片治療非酒精性脂肪肝的療效顯著，可有效降低患者脂肪肝程度，改善肝功能，具有一定臨床應用價值。

Objective To investigate the clinical effect of Danning Tablets combined with Tolynicate and Naphthylacetic Acid Tablets in treatment of non-alcoholic fatty liver. Methods Patients (102 cases) with non- alcoholic fatty liver in Xinxiang Central Hospital from July 2016 to January 2018 were randomly divided into control (51 cases) and treatment (51 cases) groups. Patients in the control group were po administered with Tolynicate and Naphthylacetic Acid Tablets 30 min before meals, 2 tablets/time, three times daily. Patients in the treatment group were po administered with Danning Tablets on the basis of the control group, 5 tablets/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the BMI, liver function, blood lipid, liver CT findings, and serum indicators in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the treatment group was 98.0%, which was significantly lower than 82.4% in the control group, and there were differences between two groups (P<0.05). After treatment, the BMI, ALT, AST, TG, and TC levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, BMI, ALT, AST, TG, and TC levels in the treatment group were lower than those in the control group, and there were differences between two groups (P<0.05). After treatment, the distribution of the severity of fatty liver and the CT value of liver/spleen in the two groups were significantly improved, and the difference was statistically significant in the same group (P<0.05). After treatment, the distribution of the severity of fatty liver and the CT value of liver/spleen in the treatment group were significantly better than those in the control group, and there were differences between two groups (P<0.05). After treatment, SOD levels was significantly increased in two groups, but MDA and TNF-α levels were significantly decreased, and there were differences in the same group (P<0.05). After treatment, SOD levels in the treatment group were higher than those in the control group, but MDA and TNF-αlevels were lower than those in the control group, and there were differences between two groups (P<0.05). Conclusion Danning Tablets combined with Tolynicate and Naphthylacetic Acid Tablets has clinical curative effect in treatment of non-alcoholic fatty liver, can effectively reduce the degree of fatty liver, and improve liver function, which has a certain clinical application value.